A Phase 1 interventional study of AZD4248 and Placebo in Chronic Kidney Disease, sponsored by AstraZeneca. Recruiting at 5 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Renal Insufficiency, Chronic by AstraZeneca — 6 open to participants now, 11 under way, 5 of them phase 3. Renal Insufficiency, Chronic · AstraZeneca.
Among the 54 studies in Renal Insufficiency, Chronic by AstraZeneca, this one is the 18th largest by planned enrollment of the 38 interventional ones that give a count, is one of 5 that started in 2025, is one of 16 in phase 1, reaches primary completion later than 2 of the 10 other live ones, and was the 47th registered.
3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.
Browse Renal Insufficiency, Chronic studies →6 of the 54 studies in Renal Insufficiency, Chronic by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Argentina, Austria and 24 more countries
Ages 18–99
AstraZeneca · Sites in United States, Argentina, Australia and 34 more countries
Ages 18+
AstraZeneca · Sites in China
AstraZeneca · Sites in United States, Argentina, Australia and 39 more countries
Ages 18+
AstraZeneca · Sites in Brazil, Chile, Costa Rica and 17 more countries
Ages 18+
By country, each count listing its studies:
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 192 is above the median of 73 across 2,162 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 170 across the 38 interventional studies, 4,000 across the 16 observational. Of the 43 that completed or were terminated, 18 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
3 of the studies in Renal Insufficiency, Chronic by AstraZeneca that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07222917AstraZenecaA Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure. | 2026-12-10 |
| NCT07024823AstraZenecaA Study to Investigate Safety, Tolerability, PK, and PD of AZD4248 in Healthy Participants, Participants With CKD and Type 2 Diabetes, Assess Home Measurements of Creatinine in a Non-Interventional Cohort, and Assess the Effect of AZD4248 on the PK of Midazolam and Metformin in Healthy Participants | 2027-01-29 |
| NCT06610526AstraZenecaA Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease | 2027-05-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 54 studies in Renal Insufficiency, Chronic by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses (SAD) and multiple ascending doses (MAD) of AZD4248 administered as an oral solution and intravenous (IV) infusion. Additionally, the study investigates the non-interventional feasibility of home measurement of serum creatinine in participants with diabetic kidney disease (DKD), and the effect of multiple doses of AZD4248 on the PK of oral midazolam and metformin.
This is a Phase I, first in human (FIH), randomized, single-blind, placebo-controlled study of AZD4248 involving healthy participants (Parts A and B) and participants with DKD (Part C), to assess home measurements of creatinine in a prospective, non-interventional cohort in participants with DKD (Part D), and assess the effect of multiple doses of AZD4248 on the PK of oral midazolam and metformin in an open-label, fixed sequence design in healthy participants (Part E).
The study consists of 5 parts:
The criteria were revised on the registry on Nov 12, 2026. See what changed
Key Inclusion Criteria:
- Healthy participants with suitable veins for cannulation or repeated venipuncture.
Parts A, B, and E:
Part C:
Part D:
Key Exclusion Criteria:
Parts A, B, and E:
Part C:
Part D:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive single ascending oral dose of AZD4248 or placebo.
Drug: AZD4248 · Drug: Placebo
Participants will receive single oral dose of AZD4248 or placebo.
Drug: AZD4248 · Drug: Placebo
Participants will receive single IV infusion of AZD4248 or placebo.
Drug: AZD4248 · Drug: Placebo
Participants will receive multiple ascending oral doses of AZD4248 or placebo.
Drug: AZD4248 · Drug: Placebo
Participants will receive multiple ascending oral doses of AZD4248 or placebo.
Drug: AZD4248 · Drug: Placebo
Participants will receive multiple oral doses of AZD4248 or placebo.
Drug: AZD4248 · Drug: Placebo
Participants will participate in home-based creatinine self-measurement.
Participants will receive a single dose of midazolam and metformin followed by multiple oral doses of AZD4248 with a single dose of midazolam and metformin.
Drug: AZD4248 · Drug: Midazolam · Drug: Metformin
AZD4248 will be administered orally.
Placebo will be administered orally.
AZD4248 will be administered via IV infusion.
Placebo will be administered via IV infusion.
Midazolam will be administered orally.
Metformin will be administered orally.
Parts A, B, and C: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
To assess the safety and tolerability of AZD4248 following single oral ascending doses or single IV administration to healthy participants and multiple oral ascending doses to healthy participants and participants with CKD and T2D (DKD).
Time frame: From Day 1 to Follow Up visit (Part A: up to 12 days; Part B and C: up to 19 days)
Part D: Intra- and inter-participant variability of estimated glomerular filtration rate (eGFR) derived from home self-testing device measurements
To assess intra- and inter-participant variability of twice weekly home-based serum creatinine measurements.
Time frame: Day 1 to Day 169
Part E: Area under concentration-time curve from time 0 to infinity (AUCinf) for midazolam
To assess the effect of AZD4248 on PK of midazolam and metformin.
Time frame: Days 1-2, 4-5, 17 and 18
Part E: Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast) for midazolam
To assess the effect of AZD4248 on PK of midazolam and metformin.
Time frame: Days 1-2, 4-5, 17 and 18
Part E: Maximum observed drug concentration (Cmax) for midazolam
To assess the effect of AZD4248 on PK of midazolam and metformin.
Time frame: Days 1-2, 4-5, 17 and 18
Part E: Ratio of Test treatment (AZD4248 + midazolam) to Reference (AZD4248) based on AUCinf (RAUCinf) of AZD4248
To assess the effect of AZD4248 on PK of midazolam and metformin.
Time frame: Days 1-2, 4-5, 17 and 18
Part E: Ratio of Test treatment (AZD4248 + midazolam) to Reference (AZD4248) based on AUClast (RAUClast) of AZD4248
To assess the effect of AZD4248 on PK of midazolam and metformin.
Time frame: Days 1-2, 4-5, 17 and 18
Part E: Ratio of Test treatment (AZD4248 + midazolam) to Reference (AZD4248) based on Cmax (RCmax) of AZD4248
To assess the effect of AZD4248 on PK of midazolam and metformin.
Time frame: Days 1-2, 4-5, 17 and 18
Part E: Terminal elimination half-life (t½λz) for midazolam
To assess the effect of AZD4248 on PK of midazolam and metformin.
Time frame: Days 1-2, 4-5, 17 and 18
Part E: Terminal rate constant (λz) for midazolam
To assess the effect of AZD4248 on PK of midazolam and metformin.
Time frame: Days 1-2, 4-5, 17 and 18
Part E: Time to reach maximum observed concentration (tmax) for midazolam
To assess the effect of AZD4248 on PK of midazolam and metformin.
Time frame: Days 1-2, 4-5, 17 and 18
Part E: AUCinf for metformin
To assess the effect of AZD4248 on PK of midazolam and metformin.
Time frame: Days 2-4, 6, and 7-16
Part E: AUClast for metformin
To assess the effect of AZD4248 on PK of midazolam and metformin.
Time frame: Days 2-4, 6, and 7-16
Part E: Cmax for metformin
To assess the effect of AZD4248 on PK of midazolam and metformin.
Time frame: Days 2-4, 6, and 7-16
Part E: Ratio of Test treatment (AZD4248 + metformin) to Reference (AZD4248) based on AUCinf (RAUCinf) of AZD4248
To assess the effect of AZD4248 on PK of midazolam and metformin.
Time frame: Days 2-4, 6, and 7-16
Part E: Ratio of Test treatment (AZD4248 + metformin) to Reference (AZD4248) based on AUClast (RAUClast) of AZD4248
To assess the effect of AZD4248 on PK of midazolam and metformin.
Time frame: Days 2-4, 6, and 7-16
Part E: Ratio of Test treatment (AZD4248 + metformin) to Reference (AZD4248) based on Cmax (RCmax) of AZD4248
To assess the effect of AZD4248 on PK of midazolam and metformin.
Time frame: Days 2-4, 6, and 7-16
Part E: Renal clearance (CLR) for metformin
To assess the effect of AZD4248 on PK of midazolam and metformin.
Time frame: Days 2-4, and 6-8
Part E: t½λz for metformin
To assess the effect of AZD4248 on PK of midazolam and metformin.
Time frame: Days 2-4, 6, and 7-16
Part E: λz for metformin
To assess the effect of AZD4248 on PK of midazolam and metformin.
Time frame: Days 2-4, 6, and 7-16
Part E: tmax for metformin
To assess the effect of AZD4248 on PK of midazolam and metformin.
Time frame: Days 2-4, 6, and 7-16
Area under concentration-time curve from time 0 to infinity (AUCinf)
To characterize the PK of AZD4248 following oral administration of single and multiple doses or a single IV administration of AZD4248. To assess the impact of food on the PK of AZD4248 following a single oral administration.
Time frame: Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17; Part E: Days 4-5, and 17-19
Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast)
To characterize the PK of AZD4248 following oral administration of single and multiple doses or a single IV administration of AZD4248. To assess the impact of food on the PK of AZD4248 following a single oral administration.
Time frame: Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17; Part E: Days 4-5, and 17-19
Dose normalized AUClast (AUClast/D)
To characterize the PK of AZD4248 following oral administration of single and multiple doses or a single IV administration of AZD4248.
Time frame: Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17
Dose normalized AUCinf (AUCinf/D)
To characterize the PK of AZD4248 following oral administration of single and multiple doses or a single IV administration of AZD4248.
Time frame: Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17
Apparent total body clearance (CL/F)
To characterize the PK of AZD4248 following oral administration of single and multiple doses or a single IV administration of AZD4248.
Time frame: Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17; Part E: Days 4-5, and 17-19
Maximum observed drug concentration (Cmax)
To characterize the PK of AZD4248 following oral administration of single and multiple doses or a single IV administration of AZD4248. To assess the impact of food on the PK of AZD4248 following a single oral administration.
Time frame: Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17; Part E: Days 4-5, and 17-19
Dose normalized Cmax (Cmax/D)
To characterize the PK of AZD4248 following oral administration of single and multiple doses or a single IV administration of AZD4248.
Time frame: Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17
Terminal elimination half-life (t½λz)
To characterize the PK of AZD4248 following oral administration of single and multiple doses or a single IV administration of AZD4248.
Time frame: Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17; Part E: Days 4-5, and 17-19
Terminal rate constant (λz)
To characterize the PK of AZD4248 following oral administration of single and multiple doses or a single IV administration of AZD4248.
Time frame: Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17; Part E: Days 4-5, and 17-19
Time delay between drug administration and the first observed concentration (tlag)
To characterize the PK of AZD4248 following oral administration of single and multiple doses or a single IV administration of AZD4248.
Time frame: Part A1 and A2: Days 1-7, Part A3: Days 1-3; Part E: Days 4-5, and 17-19
Time of last quantifiable concentration (tlast)
To characterize the PK of AZD4248 following oral administration of single and multiple doses or a single IV administration of AZD4248.
Time frame: Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17; Part E: Days 4-5, and 17-19
Time to reach maximum observed concentration (tmax)
To characterize the PK of AZD4248 following oral administration of single and multiple doses or a single IV administration of AZD4248. To assess the impact of food on the PK of AZD4248 following a single oral administration.
Time frame: Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17; Part E: Days 4-5, and 17-19
Apparent volume of distribution based on the terminal phase (Vz/F)
To characterize the PK of AZD4248 following oral administration of single and multiple doses or a single IV administration of AZD4248.
Time frame: Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17; Part E: Days 4-5, and 17-19
Absolute bioavailability (F)
To characterize the PK of AZD4248 following oral administration of single and multiple doses or a single IV administration of AZD4248.
Time frame: Part A1 and A2: Days 1-7, Part A3: Days 1-3.
Total body clearance (CL)
To characterize the PK of AZD4248 following oral administration of single and multiple doses or a single IV administration of AZD4248.
Time frame: Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17
Volume of distribution at steady state (Vss)
To characterize the PK of AZD4248 following oral administration of single and multiple doses or a single IV administration of AZD4248.
Time frame: Part A1 and A2: Days 1-7, Part A3: Days 1-3
Area under concentration-time curve in the dose interval (AUCtau)
To characterize the PK of AZD4248 following oral administration of single and multiple doses or a single IV administration of AZD4248.
Time frame: Part B: Days 1-17. Part C: Days 1-17
Dose normalized AUCtau (AUCtau/D)
To characterize the PK of AZD4248 following oral administration of single and multiple doses or a single IV administration of AZD4248.
Time frame: Part B: Days 1-17. Part C: Days 1-17
Accumulation ratio for AUC (Rac AUC)
To characterize the PK of AZD4248 following oral administration of single and multiple doses or a single IV adnminstration of AZD4248.
Time frame: Part B: Days 1-17. Part C: Days 1-17
Accumulation ratio for Cmax (Rac Cmax)
To characterize the PK of AZD4248 following oral administration of single and multiple doses or a single IV administration of AZD4248.
Time frame: Part B: Days 1-17. Part C: Days 1-17
Temporal change parameter (TCP)
To characterize the PK of AZD4248 following oral administration of single and multiple doses or a single IV administration of AZD4248.
Time frame: Part B: Days 1-17. Part C: Days 1-17
Individual and cumulative amount of unchanged drug excreted into urine from time t1 to time t2 [Ae(t1-t2)]
To characterize the PK of AZD4248 following oral administration of single and multiple doses or a single IV administration of AZD4248.
Time frame: Part A: Days 1-2. Part B: Days 1-4 and 11-14. Part C: Days 1-4 and 11-14
Individual and cumulative percentage of dose excreted unchanged in urine from time t1 to time t2 [fe(t1-t2)]
To characterize the PK of AZD4248 following oral administration of single and multiple doses or a single IV administration of AZD4248.
Time frame: Part A: Days 1-2. Part B: Days 1-4 and 11-14. Part C: Days 1-4 and 11-14
Renal clearance (CLR)
To characterize the PK of AZD4248 following oral administration of single and multiple doses or a single IV administration of AZD4248.
Time frame: Part A: Days 1-2. Part B: Days 1-4 and 11-14. Part C: Days 1-4 and 11-14
Percentage change from baseline in plasma target engagement marker
To evaluate the TE of AZD4248 by assessing reduction in plasma target engagement marker following single (oral or IV) and multiple oral dosing of AZD4248.
Time frame: Part A: Days 1-5. Part B: Days 1-4 and 11-14. Part C: Days 1-4 and 11-14
Part D: Intra- and inter-participant variability of eGFR derived from laboratory measurements
To assess the intra- and inter-participant variability of monthly laboratory-based creatinine measurements.
Time frame: Day 1 to Day 169
Part D: Changes over longitudinal follow-up in participant-reported experience questionnaire on collective participant satisfaction, usability and device acceptability data
To evaluate the usability, user satisfaction, and feasibility of delivering a home self-testing device and its accompanying smartphone application.
Time frame: Day 1 to Day 169
Part D: Summary of qualitative insights from optional individual in-depth interview samples
To evaluate the usability, user satisfaction, and feasibility of delivering a self-testing, home self-testing device and its accompanying smartphone application.
Time frame: Day 30 to Day 84
Part D: Changes over longitudinal follow-up in site-based staff reported PTSFQ
To assess clinical site staff-reported usability and satisfaction of delivering and management of the home self-testing device and software.
Time frame: Day 1 to Day 169
Part D: Estimated glomerular filtration rate (eGFR)
To compare home-based serum creatinine measurements against the standard laboratory measurements.
Time frame: Day 1 to Day 169
Part D: Proportion of completed creatinine tests, with completed assessments
To assess the rates of missing data due to missed tests or test errors.
Time frame: Day 1 to Day 169
Part E: Number of AEs and SAEs
To assess the safety and tolerability of AZD4248 alone and in combination with midazolam and metformin.
Time frame: From Day 1 to Follow Up visit (Part E: up to 24 days)
Not enrolling at this site.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Jan 2027, 19 months after the start.
Of 77 industry-sponsored phase 1 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's planned 19 months is above that.
Counting every sponsor, half of 109 studies reached it within 12 months; a quarter within 5 and three quarters within 27.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Dec 2026 → Jan 2027 and completion Dec 2026 → Jan 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Renal Insufficiency, Chronic →